Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
The prostate cancer drug Xtandi prolonged lives and delayed tumor progression when used before chemotherapy in a study of men with advanced cases of the disease, researchers said on Tuesday.
The study results are expected to open up a broader market for Xtandi, which was developed by Medivation and Astellas Pharma, and open a new front in its competition with Johnson & Johnson’s blockbuster drug Zytiga.
The cure rate of prostate cancer is highly dependent on the stage of disease at the diagnosis and early detection is key to designing effective treatment strategies. The objective of the present study is to make a specific MR imaging probe for targeted imaging of cancer cells. We take advantage of the fact that many types of prostate cancer cells express high levels of prostate-specific membrane antigen (PSMA) on their cell surface.
Computed tomography (CT)-guided percutaneous cryoablation for early-stage renal-cell carcinoma (RCC) is highly efficacious and has a favorable safety profile, researchers reported online ahead of print in Cardiovascular and Interventional Radiology.
Christos S. Georgiades, MD, of the American Medical Center in Nicosia, Cyprus, and Ron Rodriguez, MD, of the University of Texas Health Science Center in San Antonio, treated 134 patients with biopsy-proven RCC using CT-guided cryotherapy. The median tumor size was 2.8 cm. The five-year cancer-specific and overall survival was 100% and 97.8%, respectively. No patient experienced metastatic disease during follow-up.
With a deluge of promising new drug treatments for advanced prostate cancer on the market, a new model of care is needed that emphasizes collaboration between urologists and medical oncologists, according to prostate cancer experts.
Radiographic imaging of adipose tissue pointed to a risk for malignancies not normally associated with obesity, such as prostate cancer (PCa).
The first drug to treat Peyronie’s disease — an embarrassing and sometimes painful curvature of the penis — won approval on Friday from the Food and Drug Administration.
The drug, Xiaflex, is made by Auxilium Pharmaceuticals. It estimates as many as 9 percent of men have the condition, which can make intercourse painful or impossible.
Men with advanced prostate cancer survived significantly longer on a combination of two types of drugs than if they were started on the standard single treatment, according to a major federally sponsored study, which researchers suggested should change the way many such patients are treated.
The treatments involved hormone therapy to suppress levels of testosterone, the natural fuel for prostate tumors, and the chemotherapy docetaxel. Conventional practice has been to start men on testosterone suppression and then try docetaxel chemotherapy once the cancer progressed, said Christopher Sweeney, a medical oncologist at the Harvard-affiliated Dana-Farber Cancer Institute in Boston and lead investigator for the study.
But the 790-patient trial, which began in 2006, found that 69% of men who started with the combination therapy were alive after three years, compared with 52.5% who were started on hormone therapy alone, researchers said Thursday.
Study in the Journal Cell Cycle reveals new developments in prognosis
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. This sharp contrast between low-risk and aggressive disease presents a challenge for many researchers and physicians as they diagnose patients and also determine the prognosis of the men with the most aggressive forms of prostate cancer.
Researchers have discovered that the presence of a specific genetic mutation indicates a low likelihood of bladder cancer recurrence. STAG2 mutations have been observed in a number of cancers, but when Todd Waldman, MD, PhD, a cancer geneticist at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., and colleagues examined 2,214 human tumors from various body sites, they found that STAG2 was most commonly inactivated in bladder cancer. The investigators recorded truncating mutations of the STAG2 gene in 36% of the papillary noninvasive urothelial carcinomas and in 16% of the invasive urothelial carcinomas of the bladder.
The objective of this study was to examine the prognostic value of baseline health-related quality of life (HRQOL) for survival with regard to different cancer sites using 1 standardized and validated patient self-assessment tool.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.